Assertio Therapeutics Investor Presentation — December 2017

Document content

Depomed Announces NUCYNTA®

Commercialization Agreement with

Collegium Pharmaceutical

December 4, 2017Forward Looking Statements

2This presentation contains forward -looking statements within the meaning established by the Private Securities Litigation Reform

Act of 1995 ("Act"). The forward -looking statements are intended to qualify under provisions of the federal securities laws for "safe

harbor" treatment established by the Act. Forward -looking statements are based on currently available information, expectations,

estimates, assumptions and projections, and management's judgment. Words such as would, expects, intends, plans, believes,

estimates, assumes, anticipates, projects, predicts, forecasts or variations of such words or similar expressions are intende d to

identify forward -looking statements. The forward -looking statements are not guarantees of future performance. They are subject t o

risks, uncertainty and changes in circumstances. The statements that are not historical facts contained in this presentation are

forward -looking statements, including, but not limited to, those related to Depomed’s strategy, plans, objectives, expectations

(financial or otherwise) and intentions, future financial results and growth potential, including projected revenues and earn ings,

expectations regarding periods of exclusivity for the NUCYNTA®franchise, Gralise®, CAMBIA®, Zipsor®, cebranopadol , as well as

any other statements that are not historical facts. These forward -looking statements are based on Depomed’s current expectations

and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those

anticipated in such forward -looking statements as a result of these risks and uncertainties. Factors that may cause a result

different than expected or anticipated include, but are not limited to: risks associated with the commercialization of our pr oducts,

including competitive risks; risks relating to the pending ANDA litigation for Nucynta and Nucynta ER and generic entry into the

market; pricing and third party payor reimbursement risks for our products; changes in regulatory policies, procedures, and laws,

including FDA regulation of our products and regulation of our promotional practices; risks relating to the successful develo pment

of new product candidates; other risks and unforeseen events; as well as other risks related to Depomed's business detailed from

time-to-time under the caption "Risk Factors" and elsewhere in Depomed's Securities and Exchange Commission filings and